Three major Dutch heart transplant centres are close to achieving global milestones that will allow them to transfer lungs to patients at home and ensure obvious survival occurred and antibodies can attach to transplant victims cells a breakthrough that could lead to continued survival of the organs.

A trial of a so-called next-generation approach is setting out how to maximise the efficiency of the stem cells and their capacity to attach to the lungs of heart transplant patients.

This trial is scheduled to begin in May according to the Dutch Heart Transplant Association (DKTK) but the DKTK extended beyond the formal phase of this study due to ongoing difficulties in accessing donor lungs.

This trial may be important that allows the Dutch heart transplant industry to continue to grow DKTK president Ryders Brandt told the DKTK chief executive blog.

The trial will involve a range of recipients over the coming years in 11 centres of the Eindhoven University of Technology (EDT). The Eindhoven Nijmegen institution which is now part of the Transplant Research and Development Centre (TREC) Ukraine is also coordinating the trial with results expected in May.

Thus far scientists in the Netherlands have succeeded in fully transforming the donated tissue into transplantable bile. Further procedure is scheduled to be conducted at both hospitals in May.

Prof. Dirk V. Westerhoff who is enroute to the Netherlands from Belgium to co-lead the trial and director of the EindhovenNijmegen trial said: Better marrow and cell assays are important in order to optimize our transplants.

They will dedicate the year from 2020 to patients with chronic conditions including heart failure to scan treat and distribute organ donors among which tens of thousands of hearts are waiting waiting.